Background: Based on the results of phase I/II studies, S-1 plus cisplatin (CDDP) and
vinorelbine (VNR) plus CDDP are commonly used chemoradiotherapeutic regimens for the …

Aim: To evaluate the efficacy and toxicities of combination of cisplatin and oral vinorelbine
given at full doses concomitantly with radiotherapy for non-small cell lung cancer (NSCLC) …

Background Concurrent chemoradiotherapy (CCRT) is the preferred treatment for stage III
unresectable non-small cell lung cancer (NSCLC). However, there have been few reports on …

To determine the recommended phase II dose of vinorelbine in combination with cisplatin
and thoracic radiotherapy (TRT) in patients with unresectable stage III non‐small cell lung …

Introduction Concurrent chemoradiotherapy with full doses of cisplatin-based chemotherapy
is standard treatment for inoperable stage III non-small cell lung cancer (NSCLC). Although …

Background Chemotherapy is very important in treatment of advanced non-small cell lung
cancer (NSCLC), and the third-generation cisplatin-based chemotherapy regimens have …

Background: Concurrent chemoradiotherapy has improved survival in inoperable stage III
non-small cell lung cancer (NSCLC). This phase I trial was performed in order to establish a …

Chemoradiotherapy regimens for stage III non-small-cell lung cancer (NSCLC) require
ongoing evaluation. This South Australian multicentre prospective phase II study evaluated …

Background: Lung cancer is the most common cancer in the world, and causes 1.3 million
deaths annually. Approximately 45% of patients diagnosed with non-small cell lung cancer …

Aims: The aims of this study were to assess the efficacy and toxicity of concurrent
chemoradiotherapy with divided schedule of cisplatin and vinorelbine in patients with locally …